PMID- 23593747
OWN - NLM
STAT- MEDLINE
DCOM- 20130924
LR  - 20180222
IS  - 0029-0831 (Print)
IS  - 0029-0831 (Linking)
VI  - 45
IP  - 1
DP  - 2013 Jan
TI  - [An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated 
      with cyclophosphamide].
PG  - 53-7
AB  - We report on an 8-year-old boy with non-paraneoplastic anti-NMDA receptor (NMDAR) 
      encephalitis, who presented with psychotic symptoms and involuntary movement 
      following an intractable seizure. His serum and CSF tested positive for 
      anti-NMDAR antibodies. He received an initial immunotherapy consisting of 
      methylprednisolone pulse therapy (mPSL) and intravenous immunoglobulin therapy 
      (IVIg), without any clinical improvement. He had three cycles of monthly 
      cyclophosphamide pulse therapy (500 mg/m2), and his clinical condition started to 
      improve gradually two weeks after the first cycle, without any side effects. Six 
      months after onset, he tested normal upon standard neurological examination. 
      Cyclophosphamide therapy should be considered for children with anti-NMDAR 
      encephalitis, as well as mPSL and IVIg.
FAU - Mitani, Tadahiro
AU  - Mitani T
AD  - Division of Neurology, Kanagawa Children's Medical Center, Yokohama, Kanagawa.
FAU - Ohtsuka, Yoshimitsu
AU  - Ohtsuka Y
FAU - Yamamoto, Kei
AU  - Yamamoto K
FAU - Watanabe, Yoshihiro
AU  - Watanabe Y
FAU - Tsuji, Megumi
AU  - Tsuji M
FAU - Samejima, Kiyoko
AU  - Samejima K
FAU - Aida, Noriko
AU  - Aida N
FAU - Sato, Takeshi
AU  - Sato T
FAU - Wada, Takahito
AU  - Wada T
FAU - Osaka, Hitoshi
AU  - Osaka H
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - No To Hattatsu
JT  - No to hattatsu = Brain and development
JID - 0215224
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/*drug therapy
MH  - Child
MH  - Cyclophosphamide/*therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Receptors, N-Methyl-D-Aspartate/*immunology
MH  - Treatment Outcome
EDAT- 2013/04/19 06:00
MHDA- 2013/09/26 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/19 06:00 [entrez]
PHST- 2013/04/19 06:00 [pubmed]
PHST- 2013/09/26 06:00 [medline]
PST - ppublish
SO  - No To Hattatsu. 2013 Jan;45(1):53-7.